Bristol-Myers Squibb Company (BMY): $64 million was the positive money flow into the stock on Tuesday and the up/down ratio of ticks was also in favor of the bulls at 1.4. The value of trades done on upticks was $222.18 million, whereas, trades done on downticks were valued at $158.17 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $76.03 million worth stocks on upticks, which is a bullish indication. The downticks accounted only for $12.05 million worth of block trades showing a lack of interest among the large traders to sell the stock down. The up/down ratio of 6.31 was strongly in favor of the bulls. The money flow in block trades was $63.98 million. Bristol-Myers Squibb Company (BMY) fell $1.52 traded at $57.24, a change of -2.59% over the previous day. The stock is -2.6% for the week.
Also, UBS maintains their rating on the shares of Bristol-Myers Squibb Company (NYSE:BMY). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $70 per share from $80 per share. The rating by the firm was issued on August 19, 2016.
Bristol-Myers Squibb Company has lost 4.38% in the last five trading days and dropped 24.87% in the last 4 weeks. Bristol-Myers Squibb Company has dropped 19.93% during the last 3-month period . Year-to-Date the stock performance stands at -15.85%.
Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $58.97 on Tuesday but the bulls could not build on the opening and the stock topped out at $58.97 for the day. The stock traded down to $57.16 during the day, due to lack of any buying support eventually closed down at $57.24 with a loss of -2.59% for the day. The stock had closed at $58.76 on the previous day. The total traded volume was 16,800,450 shares.
In a related news, The director, of Bristol Myers Squibb Co, Andreotti Lamberto had unloaded 23,200 shares at $74.65 per share in a transaction on July 7, 2016. The total value of transaction was $1,731,880. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.